Sinovac's new crown vaccine has been discontinued! It once relied on 2.7 billion doses of vaccines to win 90 billion a year, experts appealed

Before reading this article, I sincerely invite you to click the "Follow" button, so that you can continue to push such articles in the future, and it is also convenient for you to discuss and share, your support is the driving force for us to insist on creating~

Recently, the news of Sinovac's new crown vaccine has attracted widespread attention. According to reports, Sinovac's new crown vaccine production line has stopped production, and the reason for this change may be related to the decline in its market share. However, it is worth noting that this does not mean that there is a problem with the quality of Sinovac's vaccine, but rather an adjustment of market strategy.

Over the past few years, Sinovac has achieved great success worldwide with its Covid vaccine. According to statistics, in just one year, Sinovac has earned more than 90 billion yuan by selling 2.7 billion doses of the new crown vaccine. This figure undoubtedly proves the market competitiveness of Sinovac's vaccine.

However, as time goes on, the market becomes more competitive, and other vaccine manufacturers are actively developing and promoting their own COVID vaccines. Against this backdrop, Sinovac decided to adjust its strategy and shift its limited production line to more promising vaccine research and development. The decision to discontinue production is a deliberate market decision designed to maintain the company's sustainability and market share stability.

However, experts are concerned about this. They noted that the shutdown could lead to difficulties in vaccination in some countries and regions. They called on countries to step up vaccine development, production and distribution to ensure vaccination coverage worldwide at a critical time in the global fight against the pandemic.

Overall, the discontinuation of Sinovac's COVID vaccine is an adjustment of market strategy, not a product quality issue. We look forward to Sinovac continuing to leverage its R&D strengths and making greater contributions to the global fight against the pandemic in the future."